PMID: 16644612Apr 29, 2006Paper

Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies

Advances in Therapy
R MessinJ Géczy

Abstract

Molsidomine, a sydnonimine acting as a heterocyclic direct nitric oxide donor, has been used for many years in several European countries for the treatment of patients with stable angina pectoris. The efficacy and tolerability of a novel once-daily 16-mg formulation of molsidomine (M16) were compared with those of the currently used twice-daily 8-mg molsidomine tablet (M8) in 666 patients. Study 1, a multicenter, randomized, double-blind, placebo-controlled, twin crossover study, involved 533 patients given acute and 2-week treatment with each drug formulation. Study 2, a multicenter, open-label, sequential, add-on trial, compared M16 and M8 in 133 patients. Drug effects on exercise capacity (study 1 only), frequency of anginal attacks and consumption of short-acting itroderivatives, and incidence of adverse events (AEs) were evaluated. Compared with placebo, M16 increased exercise capacity by 15% (P<.001) at the start of study 1 and by 13% (P<.001) after 2 weeks' treatment, and was not inferior to M8. In terms of anginal attack frequency and nitroderivative consumption, M16 was not inferior to M8 in either study. Moreover, compared with M8, M16 produced a statistically and clinically significant reduction in the incidence of a...Continue Reading

References

Jan 1, 1992·European Journal of Clinical Pharmacology·S RietbrockD Brockmeier
Jan 1, 1989·Journal of Cardiovascular Pharmacology·M FeelischE Noack
Jan 1, 1989·Journal of Cardiovascular Pharmacology·P M Vanhoutte
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·L J IgnarroG Chaudhuri
Jul 1, 1994·American Heart Journal·N J Mangione, S P Glasser
Aug 1, 1994·The American Journal of Cardiology·C J PepineE Handberg
May 1, 1996·Clinical Pharmacokinetics·B RosenkranzM J Parnham
Jul 23, 1998·Clinical Pharmacokinetics·R KirstenB Heintz
May 11, 2001·Drugs & Aging·A D Staniforth
Sep 22, 2001·BMJ : British Medical Journal·B S Bloom
Mar 30, 2002·Journal of the American College of Cardiology·John O ParkerWayne H Kaesemeyer
Aug 11, 2004·International Journal of Cardiology·Hemant Solomon, Robert F DeBusk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.